FDA Proposes Streamlined Registration for Distributed Manufacturing of Cell and Gene Therapies
Rationale Behind Relaxing Regulations for Distributed Manufacturing Models
The U.S. Food and Drug Administration (FDA) has proposed amendments to its regulations on July 10, 2026, to significantly simplify the registration process for distributed manufacturing facilities. The proposed changes allow companies to register a central quality control hub and multiple geographically dispersed manufacturing units (spokes) as a single manufacturing facility. Under existing regulations, each manufacturing unit had to be registered individually, which created administrative inefficiencies and increased costs. This change aims to provide pharmaceutical companies with the flexibility to quickly add, relocate, or remove production units.
Accelerating Innovation in the Cell and Gene Therapy (CGT) Market
The regulatory changes are expected to have a significant impact on the manufacturing innovation in the cell and gene therapy (CGT) sector. Personalized medicines, such as CAR-T therapies, are highly sensitive to temperature and time, making it difficult to maintain the value chain and manage logistics in traditional centralized manufacturing environments. However, with the legalization of distributed manufacturing, therapies can be produced closer to patients, such as in hospitals, reducing the risk of quality degradation during transportation. The commercialization of point-of-care technologies, such as Lonza's Cocoon platform and Orgenesis's Mobile Research Laboratory (OMPUL), will also be accelerated.
Strengthening Regulations for Overseas Manufacturing Facilities and Supply Chain Transparency
At the same time, the FDA has decided to strengthen its oversight of overseas manufacturing facilities. Previously, some companies that produced active pharmaceutical ingredients (APIs) and distributed them to other overseas facilities in the intermediate stages were not subject to FDA registration because they did not directly distribute their products to the United States. Under the revised regulations, these overseas facilities will also be required to register and report the list of drugs they are producing. This will allow the FDA to track the origin and distribution of drug ingredients entering the U.S. supply chain in real-time, significantly improving the safety of finished products.
Standardizing Quality Control and Future Market Outlook
To ensure that the relaxation of regulations does not lead to lax management of production units, the FDA plans to apply strict standards to the quality management system (QMS). Companies will be required to notify the FDA in advance when relocating their spoke facilities, and the central hub will be required to guarantee the quality of all spokes in real-time. In 2026, the cell and gene therapy manufacturing market is expected to grow to $39.7 billion, and a digitally coordinated distributed manufacturing framework is likely to become the industry standard. Ultimately, this legislation is expected to accelerate the adoption of next-generation manufacturing technologies and significantly reduce the overall production costs of biopharmaceuticals, expanding access for patients.
The FDA's proposed amendments to streamline the registration process for distributed manufacturing will facilitate the establishment of cell and gene therapy (CGT) production systems within hospital settings, providing new business opportunities for industry stakeholders. In the short term, it will significantly reduce the regulatory burden for companies offering automated manufacturing solutions, such as Lonza (LZAGY) with its Cocoon platform and Orgenesis (ORGS) with its mobile labs. In the medium to long term, it will improve the efficiency of clinical trials for personalized CAR-T therapies by enabling immediate production and administration at spoke facilities located near hospitals, eliminating the need for cold chain logistics. Furthermore, by mandating the registration of previously unregistered API facilities overseas, the proposed changes will address gaps in the raw material supply chain and enhance transparency in the $39.7 billion CGT manufacturing market by 2026. Ultimately, these amendments will serve as a key milestone in driving innovation in supply chain logistics and fostering the growth of the automated manufacturing equipment ecosystem.